Live feed
·
PRReleasevia Quantisnow
Marker Therapeutics Inc. logo

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

ByQuantisnow·Wall Street's wire, on your screen.
MRKR· Marker Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRKR (Marker Therapeutics Inc.) and more on Quantisnow.